Medtronic plc. ($MDT) Stock Forecast: Down 2.8% Today

What is Medtronic plc.?

Medtronic PLC ($MDT) is a global healthcare company that focuses on medical technology, services, and solutions. The company is recognized for its innovations in structural heart and aortic products, continuous glucose monitoring devices, and interventional cardiology.

Why is Medtronic plc. going down?

MDT stock is down 2.8% on Feb 4, 2026 16:56

• The retirement announcement of Medtronic's Senior Vice President and President of Structural Heart and Aortic, Nina Goodheart, has led to uncertainty among investors regarding future leadership and strategic direction in that segment, resulting in a bearish movement in the stock.
• Despite Medtronic's acquisition plans for CathWorks and the positive news of institutional investors increasing their stakes in the company, the market reaction may be linked to concerns about the potential impact of leadership changes on key product lines.
• The projected growth potential in the continuous glucose monitoring devices market, with a estimated market size of US$10.72 billion by 2033, might be overshadowed by worries about the immediate leadership transition within Medtronic's structural heart division.
• The current bearish movement in Medtronic's stock may stem from a combination of profit-taking following recent positive developments and investor caution regarding upcoming changes in crucial leadership positions within the company.

MDT Price Chart

MDT Technical Analysis

MDT News

Medtronic Structural Heart President Nina Goodheart to retire

Medtronic's Senior Vice President and President of Structural Heart and Aortic, Nina Goodheart, has announced her retirement after nearly two decades with the company. Goodheart, who oversaw significant advancements in technologies like the Evolut TAVR platform and Harmony TPV system, expressed profound gratitude for her time at Medtronic. She plans to retire this month, leaving the organization in a strong position.

https://www.massdevice.com/medtronic-structural-heart-president-nina-goodheart-retire/

Continuous Glucose Monitoring Devices Market to Reach US$10.72 Billion by 2033 | CAGR 8.1% | North America Leads with 42% Share | Key Players: Abbott, Dexcom, Medtronic

The global continuous glucose monitoring (CGM) devices market is projected to reach US$10.72 billion by 2033, growing at an 8.1% CAGR, up from US$5.24 billion in 2023. This growth is driven by the increasing prevalence of diabetes, technological advancements like enhanced sensor accuracy and digital health integration, and expanding use in non-insulin and pre-diabetic populations. North America currently leads the market with a 42% share, while Asia-Pacific is the fastest-growing region.

https://www.openpr.com/news/4377508/continuous-glucose-monitoring-devices-market-to-reach-us-10-72

Medtronic set to acquire CathWorks for $585m

Medtronic plans to acquire medical device company CathWorks for $585 million, exercising an option following a 2022 partnership. CathWorks specializes in diagnosing and treating coronary artery disease using its AI-powered FFRangio System. The acquisition is subject to regulatory approvals and is expected to close by the end of Medtronic's FY26.

https://www.medicaldevice-network.com/news/medtronic-to-acquire-cathworks-585m/

Equity Investment Corp Grows Stock Holdings in Medtronic PLC $MDT

Equity Investment Corp increased its stake in Medtronic PLC by 1.4% in the third quarter, making it their fifth-largest holding. Medtronic reported stronger-than-expected quarterly earnings and revenue, and institutional investors now own 82.06% of the company's stock. Medtronic also plans to acquire CathWorks to enhance its heart-imaging capabilities, and analysts generally rate the stock as a "Moderate Buy."

https://www.marketbeat.com/instant-alerts/filing-equity-investment-corp-grows-stock-holdings-in-medtronic-plc-mdt-2026-02-04/

Envestnet Asset Management Inc. Raises Stock Position in Medtronic PLC $MDT

Envestnet Asset Management Inc. increased its stake in Medtronic PLC by 5.0% in Q3, now owning 5,694,827 shares valued at $542.4 million. This move comes as Medtronic plans to acquire CathWorks for up to $585 million, enhancing its interventional cardiology portfolio, and after the company reported strong Q3 earnings, beating estimates with $1.36 EPS and $8.96B revenue. Medtronic also announced a quarterly dividend of $0.71 per share.

https://www.marketbeat.com/instant-alerts/filing-envestnet-asset-management-inc-raises-stock-position-in-medtronic-plc-mdt-2026-02-04/

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.2% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Down 10.3% Today

DaVita Inc. ($DVA) Stock Forecast: Up 5.1% Today

Skyworks Solutions Inc. ($SWKS) Stock Forecast: Up 5.2% Today

Coty Inc. Class A ($COTY) Stock Forecast: Up 5.6% Today

Rockwell Automation Inc. ($ROK) Stock Forecast: Up 8.9% Today

Intel Corporation ($INTC) Stock Forecast: Up 11.7% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 5.5% Today

Medtronic plc. Price History

04.01.2026 - MDT Stock was down 2.8%

• The retirement announcement of Medtronic's Senior Vice President and President of Structural Heart and Aortic, Nina Goodheart, has led to uncertainty among investors regarding future leadership and strategic direction in that segment, resulting in a bearish movement in the stock.
• Despite Medtronic's acquisition plans for CathWorks and the positive news of institutional investors increasing their stakes in the company, the market reaction may be linked to concerns about the potential impact of leadership changes on key product lines.
• The projected growth potential in the continuous glucose monitoring devices market, with a estimated market size of US$10.72 billion by 2033, might be overshadowed by worries about the immediate leadership transition within Medtronic's structural heart division.
• The current bearish movement in Medtronic's stock may stem from a combination of profit-taking following recent positive developments and investor caution regarding upcoming changes in crucial leadership positions within the company.

05.00.2026 - MDT Stock was up 0.7%

• Medtronic PLC (MDT) experienced a strong bullish movement today.
• The company exceeded Q3 earnings estimates, reporting $1.36 EPS and $8.96 billion in revenue, and provided a positive forecast for FY26 EPS.
• The market movement could be attributed to a firm lowering its stake in MDT by 9.9% in Q3, potentially signaling confidence in the company's future performance.
• The overall positive sentiment towards AI-powered medical stocks, including MDT, as highlighted in discussions focusing on the integration of AI in the medical sector, could have also contributed to the bullish movement.

18.10.2025 - MDT Stock was up 5.1%

• Following its Q2 earnings, Medtronic (MDT) saw a strong upward trend in its stock value, buoyed by exceeding earnings expectations and showcasing robust growth in the Cardiovascular segment.
• The company's revised 2026 outlook also bolstered investors' confidence, leading to a rise in the stock price.
• Analysts' positive forecast adjustments prior to the earnings announcement foreshadowed a strong performance, paving the way for the stock's climb post-earnings.
• Market response indicates investor trust in Medtronic's financial stability and growth opportunities, driving the stock's ascent as optimism for future success grows.

18.10.2025 - MDT Stock was up 6.0%

• Medtronic (MDT) surpassed earnings and revenue forecasts for the second quarter, demonstrating strong financial results.
• Analysts raised their projections before the earnings announcement, indicating confidence in the company's expansion opportunities.
• The optimistic projections for Medtronic's Cardiovascular unit and Diabetes segment potentially influenced the stock's upward movement, highlighting potential growth in these key sectors.
• Overall, investors reacted favorably to Medtronic's robust performance and promising future prospects, leading the stock to climb higher.